Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, B-Cell 6Lymphoma, Non-Hodgkin 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 2Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 153Dexamethasone 141Rituximab 85fludarabine 79Lenalidomide 72Cytarabine 70Bortezomib 64fludarabine phosphate 63Gemcitabine 62venetoclax 54Etoposide 53pomalidomide 52pembrolizumab 52Paclitaxel 48Cisplatin 48Carboplatin 48Peripheral Blood Stem Cell Transplantation 47Filgrastim 40Radiotherapy 39Busulfan 37Calcium Dobesilate 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 30Vincristine 29Bendamustine Hydrochloride 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × relmacabtagene autoleucel × Clear all
NCT05806580 2024-10-23

Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma

Ruijin Hospital

Phase 4 Recruiting
8 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT06479356 2024-08-21

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2 Recruiting
12 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT05814848 2023-06-15

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Changhai Hospital

Phase 4 Not yet recruiting
13 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡